Should I buy or sell Icosavax stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares. View ICVX analyst ratings or view top-rated stocks .

What is Icosavax's stock price target for 2024?

3 brokerages have issued 1-year price objectives for Icosavax's shares. Their ICVX share price targets range from $25.00 to $28.00. On average, they expect the company's share price to reach $26.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price. View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts .

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.81. The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $3.30 million.

What ETF holds Icosavax's stock?

Amplify Treatments, Testing and Advancements ETF holds 14,037 shares of ICVX stock, representing 0.78% of its portfolio.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

NASDAQ:ICVX

Icosavax (ICVX) Stock Price, News & Analysis

→ The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad)

Free ICVX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $15.31
▼
$15.31
50-Day Range: $15.31
▼
$15.45
52-Week Range: $4.75
▼
$16.10

Volume: N/A
Average Volume: 1.22 million shs
Market Capitalization: $766.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.50

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Icosavax alerts:

Icosavax MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 73.1% Upside
$26.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$229,350 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.20) to ($2.21) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

777th out of 911 stocks

Biotechnology Industry

25th out of 33 stocks

3.2

Analyst's Opinion

Consensus Rating
Icosavax has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Icosavax has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ICVX.

0.0

Dividend Strength

Dividend Yield
Icosavax does not currently pay a dividend.
Dividend Growth
Icosavax does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICVX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Icosavax this week, compared to 1 article on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Icosavax insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $229,350.00 in company stock.
Percentage Held by Insiders
30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Icosavax are expected to decrease in the coming year, from ($2.20) to ($2.21) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Icosavax has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Icosavax Stock (NASDAQ:ICVX)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ICVX Stock News Headlines

April 13, 2024 | americanbankingnews.com

Head-To-Head Analysis: Icosavax (NASDAQ:ICVX) vs. Eupraxia Pharmaceuticals (OTCMKTS:EPRXF)

March 20, 2024 | markets.businessinsider.com

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 11, 2024 | seekingalpha.com

Icosavax: Tender Offer With Contingent Value Right

January 5, 2024 | seekingalpha.com

Icosavax CVR Seems Fairly Valued

January 2, 2024 | msn.com

Guggenheim Downgrades Icosavax (ICVX)

December 31, 2023 | businesswire.com

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

December 24, 2023 | finance.yahoo.com

Chief Medical Officer Niranjan Kanesa-thasan Sells 11,884 Shares of Icosavax Inc (ICVX)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 18, 2023 | ca.finance.yahoo.com

ICVX Jul 2024 15.000 call

December 16, 2023 | finance.yahoo.com

Insider Sell Alert: Chief Business Officer Cassia Cearley Sells 8,759 Shares of Icosavax Inc (ICVX)

December 13, 2023 | finance.yahoo.com

Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know

December 13, 2023 | finance.yahoo.com

Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade

December 12, 2023 | realmoney.thestreet.com

Icosavax just downgraded at Jefferies, here's why

December 12, 2023 | msn.com

Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada

December 12, 2023 | realmoney.thestreet.com

Icosavax just downgraded at William Blair, here's why

December 12, 2023 | stockhouse.com

Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca

December 12, 2023 | tmcnet.com

ICVX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders

December 12, 2023 | markets.businessinsider.com

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

December 12, 2023 | msn.com

AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal

December 12, 2023 | finance.yahoo.com

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

December 12, 2023 | finance.yahoo.com

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

December 8, 2023 | finance.yahoo.com

Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade

December 4, 2023 | finance.yahoo.com

Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable

November 27, 2023 | msn.com

Icosavax (ICVX) Price Target Increased by 5.00% to 24.99

November 18, 2023 | msn.com

Guggenheim Initiates Coverage of Icosavax (ICVX) with Buy Recommendation

November 17, 2023 | realmoney.thestreet.com

Icosavax initiated with a Buy at Guggenheim

See More Headlines

Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ICVX
CUSIP: N/A
CIK: 1786255
Web: icosavax.com
Phone: 206-737-0085
Fax: N/A
Employees: 60
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $26.50
High Stock Price Target: $28.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +73.1%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-91,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -43.06%
Return on Assets: -39.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.06
Quick Ratio: 18.06

Sales & Book Value

Annual Sales: $580,000.00
Price / Sales: 1,322.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.47 per share
Price / Book: 2.80

Miscellaneous

Outstanding Shares: 50,090,000
Free Float: 34,767,000
Market Cap: $766.88 million
Optionable: Optionable
Beta: 1.28

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Adam K. Simpson (Age 48)
President, CEO, Co-Founder & Director
Comp: $855.95k
Mr. Niranjan Kanesa-thasan M.D. (Age 63)
Chief Medical Officer
Comp: $641.55k
Dr. Cassia Cearley Ph.D. (Age 41)
Treasurer & Chief Business Officer
Comp: $632.15k
Mr. Neil King Ph.D.
Chair of Scientific Advisory Board & Co-Founder
Dr. David Baker M.D.
Ph.D., Co-founder & Member of Scientific Advisory Board
Mr. Thomas Joseph Russo C.F.A. (Age 52)
Chief Financial Officer
Comp: $525.27k
Ms. Jennifer Raymond
Senior Vice President of Technical Operations
Ms. Elizabeth Bekiroglu (Age 54)
General Counsel & Corporate Secretary
Comp: $230.74k
Ms. Lori Stewart
Senior Vice President of People & Culture
Dr. Ami Shah Brown MPH
Ph.D., Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ICVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares.
View ICVX analyst ratings or view top-rated stocks.
What is Icosavax's stock price target for 2024?: 3 brokerages have issued 1-year price objectives for Icosavax's shares. Their ICVX share price targets range from $25.00 to $28.00. On average, they expect the company's share price to reach $26.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts.
How were Icosavax's earnings last quarter?: Icosavax, Inc. (NASDAQ:ICVX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.81. The firm had revenue of $1.83 million for the quarter, compared to the consensus estimate of $3.30 million.

What ETF holds Icosavax's stock?: Amplify Treatments, Testing and Advancements ETF holds 14,037 shares of ICVX stock, representing 0.78% of its portfolio.
When did Icosavax IPO?: Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

This page (NASDAQ:ICVX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Icosavax (ICVX) Stock Price, News & Analysis

Icosavax MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Icosavax Stock (NASDAQ:ICVX)

ICVX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ICVX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™